Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience

This study retrospectively examines the use of Janus kinase inhibitors (JAKi) in 26 patients with cutaneous T-cell lymphoma (CTCL) at a single cancer center from 2011 to 2024. Among these patients, 6 were treated with JAKi specifically for CTCL, with 4 receiving oral ruxolitinib and 2 receiving topical ruxolitinib. Notably, one patient on oral treatment achieved a complete response for 3 years, while another showed reduced lesion size over 1 year. Additionally, 9 patients received JAKi for graft versus host disease, with 5 experiencing CTCL relapse within a median of 8 weeks post-treatment. The findings suggest potential benefits of JAKi in CTCL management but highlight the need for further research to understand the safety and implications of JAKi use in CTCL patients.